Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | GABRP | O00591 | 5/20 | 0.34 |
| ▸ | GABRD | O14764 | 5/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.34 |
| ▸ | GABRE | P78334 | 5/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.34 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.34 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483959 | 0.85 | MAPT (0.47) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL6483035 | 0.77 | MEN1 (0.34) | TNKSGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6765610 | 0.77 | CYP1A2 (0.44) | TNKSALDH1A1MAPTGABRPGABRD | |
| SCHEMBL6485988 | 0.75 | DPP4 (0.38) | TNKSALDH1A1GABRPGABRDGABRA1 | |
| SCHEMBL6495849 | 0.75 | MAPT (0.37) | TNKSALDH1A1MAPTGABRPGABRD | |
| SCHEMBL6482495 | 0.74 | KCNA5 (0.38) | ALDH1A1MAPTHPGDPOLBHSD17B10 | |
| SCHEMBL6775758 | 0.74 | MAPT (0.37) | TNKSALDH1A1MAPTGABRPGABRD | |
| SCHEMBL6495063 | 0.74 | MAPT (0.35) | TNKSALDH1A1MAPTGABRPGABRD | |
| SCHEMBL6482835 | 0.73 | MEN1 (0.33) | TNKSGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6492261 | 0.73 | CCNC (0.36) | TNKSALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | claimed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | claimed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | claimed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | claimed |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | disclosed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | disclosed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | HDAC8, ZC3HAV1, ZCCHC8 | TNKS 3521/4885ALDH1A1 4486/4885MAPT 2337/4885 |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | HDAC8, CDK8, ZC3HAV1 | TNKS 4075/4885ALDH1A1 4111/4885MAPT 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.